<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005079</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA-9810046</org_study_id>
    <secondary_id>CDR0000067686</secondary_id>
    <secondary_id>UCSD-985772</secondary_id>
    <secondary_id>NCI-G00-1724</secondary_id>
    <nct_id>NCT00005079</nct_id>
  </id_info>
  <brief_title>Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer</brief_title>
  <official_title>Timing of Breast Cancer Surgery, Menstrual Cycle and Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: The timing of breast cancer surgery within the menstrual cycle may affect outcome.&#xD;
      It is not yet known if treatment is more effective during the initial or final phase of the&#xD;
      menstrual cycle.&#xD;
&#xD;
      PURPOSE: Phase III trial to determine the effect of menstrual cycle phase at surgery in&#xD;
      treating premenopausal women who have stage I, stage II, or stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine if the timing of breast surgery during the menstrual cycle impacts disease&#xD;
           recurrence, progression, or death among different racial groups in premenopausal women&#xD;
           with stage I, II, or III breast cancer.&#xD;
&#xD;
        -  Determine if definitive breast cancer surgeries (e.g., lumpectomy or mastectomy)&#xD;
           performed during the follicular phase result in poorer prognosis (recurrence, disease&#xD;
           progression, or death) compared with surgeries performed during the midcycle or luteal&#xD;
           phases in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo either fine needle aspiration concurrently with definitive breast surgery&#xD;
      (mastectomy or lumpectomy) or needle-directed excisional biopsy followed by definitive breast&#xD;
      surgery.&#xD;
&#xD;
      Patients undergo serum collection for hormonal analysis preoperatively, 24 hours post&#xD;
      operatively, at days 7 and 14, and at 3 months and urine collection for hormonal analysis&#xD;
      beginning 24 hours prior to surgery and continuing daily until the onset of the next menses.&#xD;
&#xD;
      Patients complete a 30-minute telephone interview regarding medical, family, occupational,&#xD;
      and reproductive history and lifestyle habits (e.g., diet, exercise, or environmental&#xD;
      exposures). Beginning 24 hours prior to surgery and continuing until the onset of the next&#xD;
      menses, patients complete a menstrual cycle journal indicating the start and length of&#xD;
      menses.&#xD;
&#xD;
      Patients undergoing mastectomy are followed every 3 months for 1 year, every 6 months for 1&#xD;
      year, and then annually thereafter. Patients undergoing adjuvant therapy are followed every 3&#xD;
      months for 3 years and then every 6 months thereafter or every 4 months for 2 years and then&#xD;
      every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 400 patients will be accrued for this study within 2.5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage I, II, or III primary breast cancer undergoing breast&#xD;
             surgery&#xD;
&#xD;
               -  Invasive disease (e.g., lobular or ductal)&#xD;
&#xD;
               -  No bilateral disease&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
               -  Regular menses (no amenorrhea of more than 90 days) without hormone replacement&#xD;
&#xD;
               -  Documented last menstrual period&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior malignancies&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No preoperative chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal replacement therapy&#xD;
&#xD;
          -  No concurrent interruptive oral contraceptive use of less than 3 months&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior hysterectomy and/or bilateral oophorectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena R. Chang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

